Aggarwal, S. P., L. Zinman, E. Simpson, J. McKinley, K. E. Jackson, H. Pinto, P. Kaufman, R. A. Conwit, D. Schoenfeld, J. Shefner, M. Cudkowicz, and Northeast and Canadian Amyotrophic Lateral Sclerosis Consortia. 2010. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: A randomised, double-blind, placebo-controlled trial. Lancet Neurology 9(5):481–488.
Agola, J. O., L. Hong, Z. Surviladze, O. Ursu, A. Waller, J. J. Strouse, D. S. Simpson, C. E. Schroeder, T. I. Oprea, J. E. Golden, J. Aube, T. Buranda, L. A. Sklar, and A. Wandinger–Ness. 2012. A competitive nucleotide binding inhibitor: In vitro characterization of Rab7 GTPase inhibition. ACS Chemical Biology 7(6):1095–1108.
Ashburn, T. T., and K. B. Thor. 2004. Drug repositioning: Identifying and developing new uses for existing drugs. Nature Reviews Drug Discovery 3(8):673–683.
Baker, M. 2012. Gene data to hit milestone. Nature 487(7407):282–283.
Barratt, M. J., and D. Frail. 2011. Drug repositioning: Bringing new life to shelved assets and existing drugs. Hoboken, NJ: John Wiley & Sons.
Bedlack, R., and O. Hardiman. 2009. ALSUntangled (ALSU): A scientific approach to off-label treatment options for people with ALS using tweets and twitters. Amyotrophic Lateral Sclerosis 10(3):129–130.
Bishu, K., N. Hamdani, S. F. Mohammed, M. Kruger, T. Ohtani, O. Ogut, F. V. Brozovich, J. C. Burnett, Jr., W. A. Linke, and M. M. Redfield. 2011. Sildenafil and B-type natriuretic peptide acutely phosphorylate titin and improve diastolic distensibility in vivo. Circulation 124(25):2882–2891.
Brooke, B. S., J. P. Habashi, D. P. Judge, N. Patel, B. Loeys, and H. C. Dietz, 3rd. 2008. Angiotensin II blockade and aortic-root dilation in Marfan’s syndrome. New England Journal of Medicine 358(26):2787–2795.
Chio, A., and G. Mora. 2013. The final chapter of the ALS lithium saga. Lancet Neurology 12(4):324–325.
Chong, C. R., and D. J. Sullivan, Jr. 2007. New uses for old drugs. Nature 448(7154):645–646.
Cohn, R. D., C. van Erp, J. P. Habashi, A. A. Soleimani, E. C. Klein, M. T. Lisi, M. Gamradt, C. M. ap Rhys, T. M. Holm, B. L. Loeys, F. Ramirez, D. P. Judge, C. W. Ward, and H. C. Dietz. 2007. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nature Medicine 13(2):204–210.
Cuchel, M., E. A. Meagher, H. du Toit Theron, D. J. Blom, A. D. Marais, R. A. Hegele, M. R. Averna, C. R. Sirtori, P. K. Shah, D. Gaudet, C. Stefanutti, G. B. Vigna, A. M. Du Plessis, K. J. Propert, W. J. Sasiela, L. T. Bloedon, D. J. Rader, and Phase 3 HoFH Lomitapide Study Investigators. 2013. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: A single-arm, open-label, phase 3 study. Lancet 381(9860):40–46.
Cystic Fibrosis Foundation. 2014. About cystic fibrosis. http://www.cff.org/ AboutCF (accessed January 21, 2014).
Das, J., P. Chen, D. Norris, R. Padmanabha, J. Lin, R. V. Moquin, Z. Shen, L. S. Cook, A. M. Doweyko, S. Pitt, S. Pang, D. R. Shen, Q. Fang, H. F. de Fex, K. W. McIntyre, D. J. Shuster, K. M. Gillooly, K. Behnia, G. L. Schieven, J. Wityak, and J. C. Barrish. 2006. 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. Journal of Medicinal Chemistry 49(23):6819–6832.
Dietz, H. C. 2011. Marfan syndrome. GeneReviews. http://www.ncbi.nlm.nih.gov/books/NBK1335 (accessed February 7, 2014).
Dietz, H. C., G. R. Cutting, R. E. Pyeritz, C. L. Maslen, L. Y. Sakai, G. M. Corson, E. G. Puffenberger, A. Hamosh, E. J. Nanthakumar, S. M. Curristin, G. Stetten, D. A. Meyers, and C. A. Francomano. 1991. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature 352(6333):337–339.
Dudley, J. T., T. Deshpande, and A. J. Butte. 2011a. Exploiting drug-disease relationships for computational drug repositioning. Briefings in Bioinformatics 12(4):303–311.
Dudley, J. T., M. Sirota, M. Shenoy, R. K. Pai, S. Roedder, A. P. Chiang, A. A. Morgan, M. M. Sarwal, P. J. Pasricha, and A. J. Butte. 2011b. Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Science Translational Medicine 3(96):96ra76.
Ennen, J. P., M. Verma, and A. Asakura. 2013. Vascular-targeted therapies for Duchenne muscular dystrophy. Skeletal Muscle 3(1):9.
Farooqi, S., and S. O’Rahilly. 2006. Genetics of obesity in humans. Endocrine Reviews 27(7):710–718.
Farooqi, I. S., S. A. Jebb, G. Langmack, E. Lawrence, C. H. Cheetham, A. M. Prentice, I. A. Hughes, M. A. McCamish, and S. O’Rahilly. 1999. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. New England Journal of Medicine 341(12):879–884.
FDA (U.S. Food and Drug Administration). 2012. FDA orphan products: Hope for people with rare diseases. http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm143563.htm (accessed January 21, 2014).
FDA. 2013a. FDA Center for Drug Evaluation and Research: Novel new drugs 2013 summary. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DrugInnovation/UCM381803.pdf (accessed February 11, 2014).
FDA. 2013b. A valuable resource for drug developers: The rare disease repurposing database. http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/HowtoapplyforOrphanProductDesignation/ucm216147.htm (accessed January 21, 2014).
FDA. 2013c. Frances Oldham Kelsey: Medical reviewer famous for averting a public health tragedy. http://www.fda.gov/aboutfda/whatwedo/history/ucm345094.htm (accessed January 31, 2014).
Fenn, J., and M. Raskino. 2008. Mastering the hype cycle: How to choose the right innovation at the right time. Gartner, Inc./Harvard Business School Press series. Boston, MA: Harvard Business Press.
Fornai, F., P. Longone, L. Cafaro, O. Kastsiuchenka, M. Ferrucci, M. L. Manca, G. Lazzeri, A. Spalloni, N. Bellio, P. Lenzi, N. Modugno, G. Siciliano, C. Isidoro, L. Murri, S. Ruggieri, and A. Paparelli. 2008. Lithium delays progression of amyotrophic lateral sclerosis. Proceedings of the National Academy of Sciences of the United States of America 105(6):2052–2057.
Frost, J. H., M. P. Massagli, P. Wicks, and J. Heywood. 2008. How the social web supports patient experimentation with a new therapy: The demand for patient-controlled and patient-centered informatics. AMIA Annual Symposium Proceedings 217–221.
Goldman, D. P., D. N. Lakdawalla, J. D. Malkin, J. Romley, and T. Philipson. 2011. The benefits from giving makers of conventional “small molecule” drugs longer exclusivity over clinical trial data. Health Affairs (Millwood) 30(1):84–90.
GSK (GlaxoSmithKline). 2013. GSK announces top-line results from pivotal Phase III study of darapladib in chronic coronary heart disease. http://us.gsk.com/html/media-news/pressreleases/2013/gsk-announces-topline-results-from-pivotal-phase-iii-study-of-d.html (accessed January 30, 2014).
Habashi, J. P., D. P. Judge, T. M. Holm, R. D. Cohn, B. L. Loeys, T. K. Cooper, L. Myers, E. C. Klein, G. Liu, C. Calvi, M. Podowski, E. R. Neptune, M. K. Halushka, D. Bedja, K. Gabrielson, D. B. Rifkin, L. Carta, F. Ramirez, D. L. Huso, and H. C. Dietz. 2006. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 312(5770):117–121.
Habashi, J. P., N. H., D. Bedja, G. Rykiel, J. J. Doyle, H. C. Dietz. 2012. A mechanism and treatment strategy for pregnancy-associated aortic dissection in Marfan syndrome. American Society of Human Genetics. 2012 meeting abstracts.
Holm, T. M., J. P. Habashi, J. J. Doyle, D. Bedja, Y. Chen, C. van Erp, M. E. Lindsay, D. Kim, F. Schoenhoff, R. D. Cohn, B. L. Loeys, C. J. Thomas, S. Patnaik, J. J. Marugan, D. P. Judge, and H. C. Dietz. 2011. Noncanonical TGFbeta signaling contributes to aortic aneurysm progression in Marfan syndrome mice. Science 332(6027):358–361.
Huang, R., N. Southall, Y. Wang, A. Yasgar, P. Shinn, A. Jadhav, D. T. Nguyen, and C. P. Austin. 2011. The NCGC pharmaceutical collection: A comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Science Translational Medicine 3(80):80ps16.
Hurle, M. R., L. Yang, Q. Xie, D. K. Rajpal, P. Sanseau, and P. Agarwal. 2013. Computational drug repositioning: From data to therapeutics. Clinical Pharmacology & Therapeutics 93(4):335–341.
Ito, T., H. Ando, T. Suzuki, T. Ogura, K. Hotta, Y. Imamura, Y. Yamaguchi, and H. Handa. 2010. Identification of a primary target of thalidomide teratogenicity. Science 327(5971):1345–1350.
Jang, Y., D. Waterworth, J. E. Lee, K. Song, S. Kim, H. S. Kim, K. W. Park, H. J. Cho, I. Y. Oh, J. E. Park, B. S. Lee, H. J. Ku, D. J. Shin, J. H. Lee, S. H. Jee, B. G. Han, H. Y. Jang, E. Y. Cho, P. Vallance, J. Whittaker, L. Cardon, and V. Mooser. 2011. Carriage of the V279F null allele within the gene encoding Lp-PLA(2) is protective from coronary artery disease in South Korean males. PLoS ONE 6(4):e18208.
Judge, D. P., and H. C. Dietz. 2005. Marfan’s syndrome. Lancet 366(9501):1965–1976.
Kahneman, D. 2013. Thinking, fast and slow. 1st pbk. ed. New York: Farrar, Straus and Giroux.
Kaiser, J. 2011. Biomedicine: NIH’s secondhand shop for tried-and-tested drugs. Science 332(6037):1492.
Kim, J. H., and A. R. Scialli. 2011. Thalidomide: The tragedy of birth defects and the effective treatment of disease. Toxicological Sciences 122(1):1–6.
Kuckuck, F. W., B. S. Edwards, and L. A. Sklar. 2001. High throughput flow cytometry. Cytometry 44(1):83–90.
Lacro, R. V., L. T. Guey, H. C. Dietz, G. D. Pearson, A. T. Yetman, B. D. Gelb, B. L. Loeys, D. W. Benson, T. J. Bradley, J. De Backer, G. A. Forbus, G. L. Klein, W. W. Lai, J. C. Levine, M. B. Lewin, L. W. Markham, S. M. Paridon, M. E. Pierpont, E. Radojewski, E. S. Selamet Tierney, A. M. Sharkey, S. B. Wechsler, L. Mahony, and Pediatric Heart Network Investigators. 2013. Characteristics of children and young adults with Marfan syndrome and aortic root dilation in a randomized trial comparing atenolol and losartan therapy. American Heart Journal 165(5):828–835.
Lamb, J., E. D. Crawford, D. Peck, J. W. Modell, I. C. Blat, M. J. Wrobel, J. Lerner, J. P. Brunet, A. Subramanian, K. N. Ross, M. Reich, H. Hieronymus, G. Wei, S. A. Armstrong, S. J. Haggarty, P. A. Clemons, R. Wei, S. A. Carr, E. S. Lander, and T. R. Golub. 2006. The connectivity map: Using gene-expression signatures to connect small molecules, genes, and disease. Science 313(5795):1929–1935.
Liu, Z., H. Fang, K. Reagan, X. Xu, D. L. Mendrick, W. Slikker, Jr., and W. Tong. 2013. In silico drug repositioning: What we need to know. Drug Discovery Today 18(3–4):110–115.
McBride, W. G. 1961. Thalidomide and congenital abnormalities. Lancet 278(7216):1358.
Moore, G. E. 1965. Cramming more components onto integrated circuits. Electronics 38(8): 82–85.
NHGRI (National Human Genome Research Institute). 2014. Catalog of published Genome-wide association studies. http://www.genome.gov/gwastudies (accessed January 29, 2014)
Oprea, T. I., J. E. Bauman, C. G. Bologa, T. Buranda, A. Chigaev, B. S. Edwards, J. W. Jarvik, H. D. Gresham, M. K. Haynes, B. Hjelle, R. Hromas, L. Hudson, D. A. Mackenzie, C. Y. Muller, J. C. Reed, P. C. Simons, Y. Smagley, J. Strouse, Z. Surviladze, T. Thompson, O. Ursu, A. Waller, A. Wandinger-Ness, S. S. Winter, Y. Wu, S. M. Young, R. S. Larson, C. Willman, and L. A. Sklar. 2011a. Drug repurposing from an academic perspective. Drug Discovery Today: Therapeutic Strategies 8(3–4):61–69.
Oprea, T. I., S. K. Nielsen, O. Ursu, J. J. Yang, O. Taboureau, S. L. Mathias, L. Kouskoumvekaki, L. A. Sklar, and C. G. Bologa. 2011b. Associating drugs, targets and clinical outcomes into an integrated network affords a new platform for computer-aided drug repurposing. Molecular Informatics 30(2–3):100–111.
Oral, E. A., V. Simha, E. Ruiz, A. Andewelt, A. Premkumar, P. Snell, A. J. Wagner, A. M. DePaoli, M. L. Reitman, S. I. Taylor, P. Gorden, and A. Garg. 2002. Leptin-replacement therapy for lipodystrophy. New England Journal of Medicine 346(8):570–578.
O’Sullivan, B. P., D. M. Orenstein, and C. E. Milla. 2013. Pricing for orphan drugs: Will the market bear what society cannot? JAMA 310(13):1343–1344.
Ou, S. H., C. H. Bartlett, M. Mino-Kenudson, J. Cui, and A. J. Iafrate. 2012. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: A success story to usher in the second decade of molecular targeted therapy in oncology. Oncologist 17(11):1351–1375.
Patterson, M. 2013. Niemann–Pick Disease Type C. GeneReviews. http://www.ncbi.nlm.nih.gov/books/NBK1296 (accessed January 30, 2014).
Paul, S. M., D. S. Mytelka, C. T. Dunwiddie, C. C. Persinger, B. H. Munos, S. R. Lindborg, and A. L. Schacht. 2010. How to improve R&D productivity: The pharmaceutical industry’s grand challenge. Nature Reviews Drug Discovery 9(3):203–214.
Pfizer. 2013. Pfizer reports fourth-quarter and full-year 2012 results; provides 2013 financial guidance. http://press.pfizer.com/press-release/pfizer-reports-fourth-quarter-and-full-year-2012-results-provides-2013-financial-guida (accessed January 16, 2014).
Podowski, M., C. Calvi, S. Metzger, K. Misono, H. Poonyagariyagorn, A. Lopez-Mercado, T. Ku, T. Lauer, S. McGrath-Morrow, A. Berger, C. Cheadle, R. Tuder, H. C. Dietz, W. Mitzner, R. Wise, and E. Neptune. 2012. Angiotensin receptor blockade attenuates cigarette smoke-induced lung injury and rescues lung architecture in mice. Journal of Clinical Investigations 122(1):229–240.
Sanseau, P., P. Agarwal, M. R. Barnes, T. Pastinen, J. B. Richards, L. R. Cardon, and V. Mooser. 2012. Use of genome-wide association studies for drug repositioning. Nature Biotechnology 30(4):317–320.
Scannell, J. W., A. Blanckley, H. Boldon, and B. Warrington. 2012. Diagnosing the decline in pharmaceutical R&D efficiency. Nature Reviews Drug Discovery 11(3):191–200.
Shah, N. P., C. Tran, F. Y. Lee, P. Chen, D. Norris, and C. L. Sawyers. 2004. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305(5682):399–401.
Singhal, S., J. Mehta, R. Desikan, D. Ayers, P. Roberson, P. Eddlemon, N. Munshi, E. Anaissie, C. Wilson, M. Dhodapkar, J. Zeddis, and B. Barlogie. 1999. Antitumor activity of thalidomide in refractory multiple myeloma. New England Journal of Medicine 341(21):1565–1571.
Sirota, M., J. T. Dudley, J. Kim, A. P. Chiang, A. A. Morgan, A. SweetCordero, J. Sage, and A. J. Butte. 2011. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Science Translational Medicine 3(96):96ra77.
Talpaz, M., N. P. Shah, H. Kantarjian, N. Donato, J. Nicoll, R. Paquette, J. Cortes, S. O’Brien, C. Nicaise, E. Bleickardt, M. A. Blackwood-Chirchir, V. Iyer, T. T. Chen, F. Huang, A. P. Decillis, and C. L. Sawyers. 2006. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. New England Journal of Medicine 354(24):2531–2541.
Thayer, A. M. 2012. Drug repurposing: Finding new uses for approved drugs and shelved drug candidates is gaining steam as a pharmaceutical development strategy. Chemical & Engineering News 90(40):15–25.
University of New Mexico Cancer Center. 2012. An old drug finds a new use. http://cancer.unm.edu/news-event/news-events/an-old-drug-finds-a-new-use (accessed February 11, 2014).
Wadman, M. 2012. MRC awards drug resurrection grants. Nature News Blog. http://blogs.nature.com/news/2012/10/mrc-awards-drug-resurrection-grants.html (accessed February 27, 2014).
Williamson, E. A., L. Damiani, A. Leitao, C. Hu, H. Hathaway, T. Oprea, L. Sklar, M. Shaheen, J. Bauman, W. Wang, J. A. Nickoloff, S. H. Lee, and R. Hromas. 2012. Targeting the transposase domain of the DNA repair component metnase to enhance chemotherapy. Cancer Research 72(23):6200–6208.
Zhang, Y., R. Proenca, M. Maffei, M. Barone, L. Leopold, and J. M. Friedman. 1994. Positional cloning of the mouse obese gene and its human homologue. Nature 372(6505):425–432.
